JP7830441B2 - Ｇｌｐ－１／ｇｉｐ二重アゴニスト - Google Patents

Ｇｌｐ－１／ｇｉｐ二重アゴニスト

Info

Publication number
JP7830441B2
JP7830441B2 JP2023519770A JP2023519770A JP7830441B2 JP 7830441 B2 JP7830441 B2 JP 7830441B2 JP 2023519770 A JP2023519770 A JP 2023519770A JP 2023519770 A JP2023519770 A JP 2023519770A JP 7830441 B2 JP7830441 B2 JP 7830441B2
Authority
JP
Japan
Prior art keywords
ser
tbu
group
gly
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023519770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545662A5 (https=
JP2023545662A (ja
Inventor
セナティ，ラジャマンナル
ブラデ，ヴィノド・サンパタラオ
ナタラジャン，ムスクマラン
ジョシ，ディレン・ラメシュチャンドラ
ガンディー，マニシュ・ハレンドラプラサド
ジヴァニ，チャンドゥーラル・サカールシバーイー
ティワリ，アビセーク
ソニ，クルーナル・ハリシュバーイー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Sun Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Industries Ltd filed Critical Sun Pharmaceutical Industries Ltd
Publication of JP2023545662A publication Critical patent/JP2023545662A/ja
Publication of JP2023545662A5 publication Critical patent/JP2023545662A5/ja
Application granted granted Critical
Publication of JP7830441B2 publication Critical patent/JP7830441B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Theoretical Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Data Mining & Analysis (AREA)
  • Software Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Artificial Intelligence (AREA)
JP2023519770A 2020-10-17 2021-10-13 Ｇｌｐ－１／ｇｉｐ二重アゴニスト Active JP7830441B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN202021045240 2020-10-17
IN202021045240 2020-10-17
IN202121002837 2021-01-20
IN202121002837 2021-01-20
PCT/IB2021/059420 WO2022079639A1 (en) 2020-10-17 2021-10-13 Glp-1/gip dual agonists

Publications (3)

Publication Number Publication Date
JP2023545662A JP2023545662A (ja) 2023-10-31
JP2023545662A5 JP2023545662A5 (https=) 2024-10-18
JP7830441B2 true JP7830441B2 (ja) 2026-03-16

Family

ID=78302859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023519770A Active JP7830441B2 (ja) 2020-10-17 2021-10-13 Ｇｌｐ－１／ｇｉｐ二重アゴニスト

Country Status (16)

Country Link
US (2) US20240020543A1 (https=)
EP (1) EP4204440A1 (https=)
JP (1) JP7830441B2 (https=)
KR (1) KR20230088337A (https=)
CN (1) CN116171164A (https=)
AU (1) AU2021361263A1 (https=)
BR (1) BR112023003668A2 (https=)
CA (1) CA3195155A1 (https=)
CL (1) CL2023000960A1 (https=)
CO (1) CO2023001960A2 (https=)
IL (1) IL301109A (https=)
JO (1) JOP20230077A1 (https=)
MX (1) MX2023002906A (https=)
PE (1) PE20231309A1 (https=)
TW (1) TW202229323A (https=)
WO (1) WO2022079639A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
US12281149B2 (en) 2021-05-13 2025-04-22 Carmot Therapeutics, Inc. Modulators of G-protein coupled receptors
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
EP4556487A1 (en) * 2022-07-13 2025-05-21 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. Glp-1/gip dual agonist, and preparation method therefor and use thereof
WO2024020388A1 (en) * 2022-07-20 2024-01-25 Viking Therapeutics, Inc. Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
WO2024098718A1 (zh) * 2022-11-07 2024-05-16 内蒙古博睿精创科技有限公司 一种新型长效多肽化合物、组合物及其应用
CN115651075B (zh) * 2022-12-12 2023-04-11 杭州信海医药科技有限公司 一种Tirzepatide的合成方法
CN120865433A (zh) * 2022-12-21 2025-10-31 勃林格殷格翰国际有限公司 Glp1/gip/npy2受体的三重激动剂
JP2025530024A (ja) * 2023-01-18 2025-09-10 シャンハイ ミンウェイ バイオテクノロジー カンパニー，リミテッド 三重活性を有する融合タンパク質およびその応用
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
TW202500575A (zh) * 2023-05-21 2025-01-01 美商卡默療法股份有限公司 具有或不具有體重相關合併症之過重或肥胖成人之治療
KR20260022948A (ko) 2023-06-09 2026-02-20 썬 파마슈티컬 인더스트리스 리미티드 Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
CN116693652B (zh) * 2023-08-02 2024-01-05 北京惠之衡生物科技有限公司 一种glp-1/gip受体双重激动剂衍生物及其制备方法和应用
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025133348A1 (en) 2023-12-22 2025-06-26 E-Therapeutics Plc Inhibitors of expression and/or function
WO2025149039A1 (zh) * 2024-01-12 2025-07-17 杭州中美华东制药有限公司 长效glp-1/gip双激动剂的药物组合物
WO2025163615A1 (en) 2024-01-31 2025-08-07 Sun Pharmaceutical Industries Ltd. High level production of glp1 analogues
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009528824A (ja) 2006-03-03 2009-08-13 カリフォルニア インスティチュート オブ テクノロジー 分子へのアミノ酸の部位特異的な組み込み
JP2015517459A (ja) 2012-05-03 2015-06-22 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2016540741A (ja) 2013-11-06 2016-12-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2017507124A (ja) 2015-01-09 2017-03-16 イーライ リリー アンド カンパニー Ｇｉｐおよびｇｌｐ−１コアゴニスト化合物
WO2019193576A1 (en) 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
WO2019245893A2 (en) 2018-06-22 2019-12-26 Eli Lilly And Company Gip/glp1 agonist compositions
WO2020023388A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Method of using a gip/glp1 co-agonist for diabetes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104583232B (zh) * 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 展现gip受体活性的胰高血糖素类似物
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
KR20240051304A (ko) 2018-07-23 2024-04-19 일라이 릴리 앤드 캄파니 Gip/glp1 공효능제 화합물
TW202216746A (zh) * 2020-06-22 2022-05-01 印度商太陽製藥工業有限公司 長效型ｇｌｐ－１／ｇｉｐ雙重促效劑

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009528824A (ja) 2006-03-03 2009-08-13 カリフォルニア インスティチュート オブ テクノロジー 分子へのアミノ酸の部位特異的な組み込み
JP2015517459A (ja) 2012-05-03 2015-06-22 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2016540741A (ja) 2013-11-06 2016-12-28 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
JP2017507124A (ja) 2015-01-09 2017-03-16 イーライ リリー アンド カンパニー Ｇｉｐおよびｇｌｐ−１コアゴニスト化合物
WO2019193576A1 (en) 2018-04-05 2019-10-10 Sun Pharmaceutical Industries Limited Novel glp-1 analogues
WO2019245893A2 (en) 2018-06-22 2019-12-26 Eli Lilly And Company Gip/glp1 agonist compositions
WO2020023388A1 (en) 2018-07-23 2020-01-30 Eli Lilly And Company Method of using a gip/glp1 co-agonist for diabetes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Molecular Metabolism，2018年，Vol.18，pp.3-14

Also Published As

Publication number Publication date
WO2022079639A1 (en) 2022-04-21
JOP20230077A1 (ar) 2023-04-16
CL2023000960A1 (es) 2023-11-10
EP4204440A1 (en) 2023-07-05
US20240020543A1 (en) 2024-01-18
PE20231309A1 (es) 2023-08-24
US20240400613A1 (en) 2024-12-05
JP2023545662A (ja) 2023-10-31
CN116171164A (zh) 2023-05-26
CA3195155A1 (en) 2022-04-21
TW202229323A (zh) 2022-08-01
KR20230088337A (ko) 2023-06-19
AU2021361263A1 (en) 2023-02-16
CO2023001960A2 (es) 2023-05-08
IL301109A (en) 2023-05-01
MX2023002906A (es) 2023-04-05
BR112023003668A2 (pt) 2023-04-25

Similar Documents

Publication Publication Date Title
JP7830441B2 (ja) Ｇｌｐ－１／ｇｉｐ二重アゴニスト
JP7849310B2 (ja) 長時間作用性ｇｌｐ－１／ｇｉｐデュアルアゴニスト
CN103200966B (zh) 具有接头的双-酰化的glp-1衍生物
KR102801994B1 (ko) 신규한 glp-1 유사체
JP6297969B2 (ja) 部位特異的モノｐｅｇ化エキセンジン類似体およびその調製方法
JP2024147650A (ja) インクレチン類似体を作製する方法
EP1575490A2 (en) Modified glucagon-like peptide-1 analogs
EP3233898A1 (en) Glp-1 derivatives and uses thereof
WO2015149627A1 (zh) 结构修饰的glp-1类似物及其制备方法
JP2025508820A (ja) Ｃｒｆ２受容体アゴニスト及び治療法におけるそれらの使用
WO2022007805A1 (zh) 新型多肽及其治疗用途
EP4638481A1 (en) Glp1/gip/npy2 receptor triple agonists
CN119656289A (zh) 带有修饰结构的多肽及其应用
EA053025B1 (ru) Двойные агонисты glp-1/gip
CN1683408A (zh) 胰高血糖素样肽类似物、其组合物及其使用方法
WO2025257294A1 (en) Soluble glp1/gip/npy2 receptor triple agonists
CN119488582A (zh) 一种glp-1和pyy孪药及其制备方法和应用
KR20260022948A (ko) Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제
CN119930756A (zh) 一种gip和glp-1的双受体激动剂的制备方法
JPH10310600A (ja) 新規生理活性ペプチド及びその用途
JP2023538871A (ja) エキセンジン－４ペプチド類似体
JP2002293799A (ja) 新規ペプチド及びそれを含有する消化管運動抑制剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260210

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260304

R150 Certificate of patent or registration of utility model

Ref document number: 7830441

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150